Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 85
Filtrar
1.
Res Synth Methods ; 15(2): 257-274, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38044791

RESUMEN

Predatory journals are a blemish on scholarly publishing and academia and the studies published within them are more likely to contain data that is false. The inclusion of studies from predatory journals in evidence syntheses is potentially problematic due to this propensity for false data to be included. To date, there has been little exploration of the opinions and experiences of evidence synthesisers when dealing with predatory journals in the conduct of their evidence synthesis. In this paper, the thoughts, opinions, and attitudes of evidence synthesisers towards predatory journals and the inclusion of studies published within these journals in evidence syntheses were sought. Focus groups were held with participants who were experienced evidence synthesisers from JBI (previously the Joanna Briggs Institute) collaboration. Utilising qualitative content analysis, two generic categories were identified: predatory journals within evidence synthesis, and predatory journals within academia. Our findings suggest that evidence synthesisers believe predatory journals are hard to identify and that there is no current consensus on the management of these studies if they have been included in an evidence synthesis. There is a critical need for further research, education, guidance, and development of clear processes to assist evidence synthesisers in the management of studies from predatory journals.


Asunto(s)
Publicaciones Periódicas como Asunto , Humanos , Encuestas y Cuestionarios , Investigación Cualitativa
2.
Res Synth Methods ; 14(3): 370-381, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-36605026

RESUMEN

Synthesizers of evidence are increasingly likely to encounter studies published in predatory journals during the evidence synthesis process. The evidence synthesis discipline is uniquely positioned to encounter novel concerns associated with predatory journals. The objective of this research was to explore the attitudes, opinions, and experiences of experts in the synthesis of evidence regarding predatory journals. Employing a descriptive survey-based cross-sectional study design, these experts were asked a series of questions regarding predatory journals to explore these attitudes, opinions, and experiences. Two hundred and sixty four evidence synthesis experts responded to this survey. Most respondents agreed with the definition of a predatory journal (86%), however several (19%) responded that this definition was difficult to apply practically. Many respondents believed that studies published in predatory journals are still eligible for inclusion into an evidence synthesis project. However, this was only after the study had been determined to be 'high-quality' (39%) or if the results were validated (13%). While many respondents could identify common characteristics of these journals, there was still hesitancy regarding the appropriate methods to follow when considering including these studies into an evidence synthesis project.


Asunto(s)
Publicaciones Periódicas como Asunto , Estudios Transversales , Encuestas y Cuestionarios
3.
Artículo en Portugués | PAHO-IRIS | ID: phr-56882

RESUMEN

[RESUMO]. A declaração dos Principais Itens para Relatar Revisões Sistemáticas e Meta-análises (PRISMA), publicada em 2009, foi desenvolvida para ajudar revisores sistemáticos a relatar de forma transparente por que a revisão foi feita, os métodos empregados e o que os autores encontraram. Na última década, os avanços na metodo- logia e terminologia de revisões sistemáticas exigiram a atualização da diretriz. A declaração PRISMA 2020 substitui a declaração de 2009 e inclui novas orientações para relato que refletem os avanços nos métodos para identificar, selecionar, avaliar e sintetizar estudos. A estrutura e apresentação dos itens foram modifi- cadas para facilitar a implementação. Neste artigo, apresentamos a lista de checagem PRISMA 2020 de 27 itens, uma lista de checagem expandida que detalha as recomendações para relato para cada item, a lista de checagem PRISMA 2020 para resumos e os fluxogramas revisados para novas revisões e para atualização de revisões.


[ABSTRACT]. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate imple- mentation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.


[RESUMEN]. La declaración PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), publicada en 2009, se diseñó para ayudar a los autores de revisiones sistemáticas a documentar de manera transparente el porqué de la revisión, qué hicieron los autores y qué encontraron. Durante la última década, ha habido muchos avances en la metodología y terminología de las revisiones sistemáticas, lo que ha requerido una actualización de esta guía. La declaración PRISMA 2020 sustituye a la declaración de 2009 e incluye una nueva guía de presentación de las publicaciones que refleja los avances en los métodos para identificar, seleccionar, evaluar y sintetizar estudios. La estructura y la presentación de los ítems ha sido modificada para facilitar su implementación. En este artículo, presentamos la lista de verificación PRISMA 2020 con 27 ítems, y una lista de verificación ampliada que detalla las recomendaciones en la publicación de cada ítem, la lista de verificación del resumen estructurado PRISMA 2020 y el diagrama de flujo revisado para revisiones sistemáticas.


Asunto(s)
Guía , Revisión Sistemática , Metaanálisis , Escritura Médica , Guía , Revisión Sistemática , Metaanálisis , Escritura Médica , Guía , Revisión Sistemática , Metaanálisis , Escritura Médica
4.
BMJ Open ; 12(5): e056875, 2022 05 19.
Artículo en Inglés | MEDLINE | ID: mdl-35589369

RESUMEN

INTRODUCTION: Health inequities are defined as unfair and avoidable differences in health between groups within a population. Most health research is conducted through observational studies, which are able to offer real-world insights about etiology, healthcare policy/programme effectiveness and the impacts of socioeconomic factors. However, most published reports of observational studies do not address how their findings relate to health equity. Our team seeks to develop equity-relevant reporting guidance as an extension of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. This scoping review will inform the development of candidate items for the STROBE-Equity extension. We will operationalise equity-seeking populations using the PROGRESS-Plus framework of sociodemographic factors. As part of a parallel stream of the STROBE-Equity project, the relevance of candidate guideline items to Indigenous research will be led by Indigenous coinvestigators on the team. METHODS AND ANALYSIS: We will follow the Joanna Briggs Institute method for conducting scoping reviews. We will evaluate the extent to which the identified guidance supports or refutes our preliminary candidate items for reporting equity in observational studies. These candidate items were developed based on items from equity-reporting guidelines for randomised trials and systematic reviews, developed by members of this team. We will consult with our knowledge users, patients/public partners and Indigenous research steering committee to invite suggestions for relevant guidance documents and interpretation of findings. If the identified guidance suggests the need for additional candidate items, they will be developed through inductive thematic analysis. ETHICS AND DISSEMINATION: We will follow a principled approach that promotes ethical codevelopment with our community partners, based on principles of cultural safety, authentic partnerships, addressing colonial structures in knowledge production and the shared ownership, interpretation, and dissemination of research. All products of this research will be published as open access.


Asunto(s)
Equidad en Salud , Humanos , Grupos de Población , Proyectos de Investigación , Informe de Investigación , Literatura de Revisión como Asunto , Factores Socioeconómicos
5.
Rev Panam Salud Publica ; 46: e112, 2022.
Artículo en Portugués | MEDLINE | ID: mdl-36601438

RESUMEN

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.


La declaración PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), publicada en 2009, se diseñó para ayudar a los autores de revisiones sistemáticas a documentar de manera transparente el porqué de la revisión, qué hicieron los autores y qué encontraron. Durante la última década, ha habido muchos avances en la metodología y terminología de las revisiones sistemáticas, lo que ha requerido una actualización de esta guía. La declaración PRISMA 2020 sustituye a la declaración de 2009 e incluye una nueva guía de presentación de las publicaciones que refleja los avances en los métodos para identificar, seleccionar, evaluar y sintetizar estudios. La estructura y la presentación de los ítems ha sido modificada para facilitar su implementación. En este artículo, presentamos la lista de verificación PRISMA 2020 con 27 ítems, y una lista de verificación ampliada que detalla las recomendaciones en la publicación de cada ítem, la lista de verificación del resumen estructurado PRISMA 2020 y el diagrama de flujo revisado para revisiones sistemáticas.

6.
Rev. panam. salud pública ; 46: e112, 2022. tab, graf
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1450192

RESUMEN

RESUMO A declaração dos Principais Itens para Relatar Revisões Sistemáticas e Meta-análises (PRISMA), publicada em 2009, foi desenvolvida para ajudar revisores sistemáticos a relatar de forma transparente por que a revisão foi feita, os métodos empregados e o que os autores encontraram. Na última década, os avanços na metodologia e terminologia de revisões sistemáticas exigiram a atualização da diretriz. A declaração PRISMA 2020 substitui a declaração de 2009 e inclui novas orientações para relato que refletem os avanços nos métodos para identificar, selecionar, avaliar e sintetizar estudos. A estrutura e apresentação dos itens foram modificadas para facilitar a implementação. Neste artigo, apresentamos a lista de checagem PRISMA 2020 de 27 itens, uma lista de checagem expandida que detalha as recomendações para relato para cada item, a lista de checagem PRISMA 2020 para resumos e os fluxogramas revisados para novas revisões e para atualização de revisões.


ABSTRACT The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.


RESUMEN La declaración PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), publicada en 2009, se diseñó para ayudar a los autores de revisiones sistemáticas a documentar de manera transparente el porqué de la revisión, qué hicieron los autores y qué encontraron. Durante la última década, ha habido muchos avances en la metodología y terminología de las revisiones sistemáticas, lo que ha requerido una actualización de esta guía. La declaración PRISMA 2020 sustituye a la declaración de 2009 e incluye una nueva guía de presentación de las publicaciones que refleja los avances en los métodos para identificar, seleccionar, evaluar y sintetizar estudios. La estructura y la presentación de los ítems ha sido modificada para facilitar su implementación. En este artículo, presentamos la lista de verificación PRISMA 2020 con 27 ítems, y una lista de verificación ampliada que detalla las recomendaciones en la publicación de cada ítem, la lista de verificación del resumen estructurado PRISMA 2020 y el diagrama de flujo revisado para revisiones sistemáticas.

7.
Artículo en Inglés | MEDLINE | ID: mdl-34501949

RESUMEN

The COVID-19 pandemic has highlighted the global imperative to address health inequities. Observational studies are a valuable source of evidence for real-world effects and impacts of implementing COVID-19 policies on the redistribution of inequities. We assembled a diverse global multi-disciplinary team to develop interim guidance for improving transparency in reporting health equity in COVID-19 observational studies. We identified 14 areas in the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist that need additional detail to encourage transparent reporting of health equity. We searched for examples of COVID-19 observational studies that analysed and reported health equity analysis across one or more social determinants of health. We engaged with Indigenous stakeholders and others groups experiencing health inequities to co-produce this guidance and to bring an intersectional lens. Taking health equity and social determinants of health into account contributes to the clinical and epidemiological understanding of the disease, identifying specific needs and supporting decision-making processes. Stakeholders are encouraged to consider using this guidance on observational research to help provide evidence to close the inequitable gaps in health outcomes.


Asunto(s)
COVID-19 , Equidad en Salud , Humanos , Pandemias , SARS-CoV-2 , Justicia Social
8.
Rev Esp Cardiol (Engl Ed) ; 74(9): 790-799, 2021 Sep.
Artículo en Inglés, Español | MEDLINE | ID: mdl-34446261

RESUMEN

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews. Full English text available from:www.revespcardiol.org/en.


Asunto(s)
Lista de Verificación , Edición , Humanos
9.
ALTEX ; 38(3): 513-522, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34164697

RESUMEN

Systematic reviews are fast increasing in prevalence in the toxicology and environmental health literature. However, how well these complex research projects are being conducted and reported is unclear. Since editors have an essential role in ensuring the scientific quality of manuscripts being published in their journals, a workshop was convened where editors, systematic review practitioners, and research quality control experts could discuss what editors can do to ensure the systematic reviews they publish are of sufficient scientific quality. Interventions were explored along four themes: setting standards; reviewing protocols; optimizing editorial workflows; and measuring the effectiveness of editorial interventions. In total, 58 editorial interventions were proposed. Of these, 26 were shortlisted for being potentially effective, and 5 were prioritized as short-term actions that editors could relatively easily take to improve the quality of published systematic reviews. Recent progress in improving systematic reviews is summarized, and outstanding challenges to further progress are highlighted.


Asunto(s)
Políticas Editoriales , Salud Ambiental , Control de Calidad , Flujo de Trabajo
10.
JBI Evid Synth ; 19(8): 1915-1923, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-34171895

RESUMEN

ABSTRACT: A systematic review involves the identification, evaluation, and synthesis of the best-available evidence to provide an answer to a specific question. The "best-available evidence" is, in many cases, a peer-reviewed scientific article published in an academic journal that details the conduct and results of a scientific study. Any potential threat to the validity of these individual studies (and hence the resultant synthesis) must be evaluated and critiqued.In science, the number of predatory journals continue to rise. Studies published in predatory journals may be of lower quality and more likely to be impacted by fraud and error compared to studies published in traditional journals. This poses a threat to the validity of systematic reviews that include these studies and, therefore, the translation of evidence into guidance for policy and practice. Despite the challenges predatory journals present to systematic reviewers, there is currently little guidance regarding how they should be managed.In 2020, a subgroup of the JBI Scientific Committee was formed to investigate this issue. In this overview paper, we introduce predatory journals to systematic reviewers, outline the problems they present and their potential impact on systematic reviews, and provide some alternative strategies for consideration of studies from predatory journals in systematic reviews. Options for systematic reviewers could include excluding all studies from suspected predatory journals, applying additional strategies to forensically examine the results of studies published in suspected predatory journals, setting stringent search limits, and applying analytical techniques (such as subgroup or sensitivity analyses) to investigate the impact of suspected predatory journals in a synthesis.


Asunto(s)
Publicaciones Periódicas como Asunto , Revisión por Pares , Informe de Investigación , Revisiones Sistemáticas como Asunto
11.
F1000Res ; 10: 100, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33953906

RESUMEN

Background: Funded health research is being published in journals that many regard as "predatory", deceptive, and non-credible. We do not currently know whether funders provide guidance on how to select a journal in which to publish funded health research. Methods: We identified the largest 46 philanthropic, public, development assistance, public-private partnership, and multilateral funders of health research by expenditure, globally as well as four public funders from lower-middle income countries, from the list at https://healthresearchfunders.org. One of us identified guidance on disseminating funded research from each funders' website (August/September 2017), then extracted information about selecting journals, which was verified by another assessor. Discrepancies were resolved by discussion. Results were summarized descriptively. This research used publicly available information; we did not seek verification with funding bodies. Results: The majority (44/50) of sampled funders indicated funding health research. 38 (of 44, 86%) had publicly available information about disseminating funded research, typically called "policies" (29, 76%). Of these 38, 36 (95%) mentioned journal publication for dissemination of which 13 (36.11%) offer variable guidance on selecting a journal, all of which relate to the funder's open access mandate. Six funders (17%) outlined publisher requirements or features by which to select a journal. One funder linked to a document providing features of journals to look for (e.g. listed in the Directory of Open Access Journals) and to be wary of (e.g., no journal scope statement, uses direct and unsolicited marketing). Conclusions: Few funders provided guidance on how to select a journal in which to publish funded research. Funders have a duty to ensure that the research they fund is discoverable by others. This research is a benchmark for funder guidance on journal selection prior to the January 2021 implementation of Plan S (a global, funder-led initiative to ensure immediate, open access to funded, published research).


Asunto(s)
Publicaciones Periódicas como Asunto
12.
J Clin Epidemiol ; 134: 178-189, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33789819

RESUMEN

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.


Asunto(s)
Proyectos de Investigación/normas , Revisiones Sistemáticas como Asunto/métodos , Medicina Basada en la Evidencia , Guías como Asunto , Humanos , Revisiones Sistemáticas como Asunto/normas
13.
Int J Surg ; 88: 105906, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33789826

RESUMEN

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.


Asunto(s)
Guías como Asunto , Informe de Investigación/normas , Revisiones Sistemáticas como Asunto , Lista de Verificación , Humanos , Edición
18.
J Clin Epidemiol ; 134: 160-166, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33705957

RESUMEN

COVID-19 has disproportionately placed women in academic science on the frontlines of domestic and clinical care compared to men. As a result, women in science are publishing less and potentially acquiring less funding during COVID-19 than compared to before. This widens the pre-existing gap between men and women in prevailing, publication-based measures of productivity used to determine academic career progression. Early career women and those with intersectional identities associated with greater inequities, are facing unique challenges during this time. We argue that women will fall further behind unless academic reward systems adjust how and what they evaluate. We propose several strategies that academic institutions, funders, journals, and men in academic science can take.


Asunto(s)
Investigación Biomédica/estadística & datos numéricos , COVID-19/epidemiología , Movilidad Laboral , Eficiencia , Edición/estadística & datos numéricos , Adulto , Femenino , Humanos , Pandemias , SARS-CoV-2 , Factores Sexuales
19.
J Clin Epidemiol ; 134: 103-112, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33577987

RESUMEN

OBJECTIVES: To describe the processes used to update the PRISMA 2009 statement for reporting systematic reviews, present results of a survey conducted to inform the update, summarize decisions made at the PRISMA update meeting, and describe and justify changes made to the guideline. METHODS: We reviewed 60 documents with reporting guidance for systematic reviews to generate suggested modifications to the PRISMA 2009 statement. We invited 220 systematic review methodologists and journal editors to complete a survey about the suggested modifications. The results of these projects were discussed at a 21-member in-person meeting. Following the meeting, we drafted the PRISMA 2020 statement and refined it based on feedback from co-authors and a convenience sample of 15 systematic reviewers. RESULTS: The review of 60 documents revealed that all topics addressed by the PRISMA 2009 statement could be modified. Of the 110 survey respondents, more than 66% recommended keeping six of the original checklist items as they were and modifying 15 of them using wording suggested by us. Attendees at the in-person meeting supported the revised wording for several items but suggested rewording for most to enhance clarity, and further refinements were made over six drafts of the guideline. CONCLUSIONS: The PRISMA 2020 statement consists of updated reporting guidance for systematic reviews. We hope that providing this detailed description of the development process will enhance the acceptance and uptake of the guideline and assist those developing and updating future reporting guidelines.


Asunto(s)
Guías como Asunto/normas , Informe de Investigación/normas , Consenso , Medicina Basada en la Evidencia , Adhesión a Directriz , Humanos , Encuestas y Cuestionarios , Revisiones Sistemáticas como Asunto
20.
Campbell Syst Rev ; 17(1): e1134, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-37133262

RESUMEN

Background: The Campbell Collaboration undertakes systematic reviews of the effects of social and economic policies (interventions) to help policymakers, practitioners, and the public to make well-informed decisions about policy interventions. In 2010, the Cochrane Collaboration and the Campbell Collaboration developed a voluntary co-registration policy under the rationale to make full use of the shared interests and diverse expertise from different review groups within these two organizations. In order to promote the methodological quality and transparency of Campbell intervention reviews, the Methodological Expectations of Campbell Collaboration Intervention Reviews (MECCIR) were introduced in 2014 to guide Campbell reviewers. However, there has not been a comprehensive review of the methodological quality and reporting characteristics of Campbell reviews. Objectives: This review aimed to assess the methodological and reporting characteristics of Campbell intervention reviews and to compare the methodological quality and reporting completeness of Campbell reviews published before and after the implementation of MECCIR. A secondary aim was to compare the methodological quality and reporting completeness of reviews registered with Campbell only versus those co-registered with Cochrane and Campbell. Search Methods: We searched the Campbell Library to identify all the completed intervention reviews published between 1 January 2011 to 31 January 2018. Selection Criteria: One researcher downloaded and screened all the records to exclude non-intervention reviews based on reviews' title and abstract. A second researcher checked the full text of all the excluded records to confirm the exclusion. In case of discrepancies, the two researchers jointly agreed on the final decision. Data Collection and Analysis: We developed the abstraction form based on mandatory reporting items for methods, results, and discussion from the MECCIR reporting standards Version 1.1; and additional epidemiological characteristics identified in a similar study of systematic reviews in health. Additionally, we judged the methodological quality and completeness of reporting of each included review. For methodological quality, we used the AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews 2) instrument; for reporting completeness we used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist. We rated reporting as either complete/partial or not reported. We described characteristics of the included reviews with frequencies and percentages, and median with interquartile ranges (IQRs). We used Stata version 12.0 to conduct multiple linear regressions for continuous data and the ordered logistic regressions for ordered data to investigate associations between prespecified factors and both methodological quality and completeness of reporting. Main Results: We included 96 Campbell reviews, 46 were published between January 2011 and September 2014 (pre-MECCIR) and 50 between October 2014 and January 2018 (post-MECCIR). Twenty-two of 96 (23%) reviews were co-registered with Cochrane. For overall methodological quality, 16 (17%) reviews were rated as high, 40 (42%) as moderate, 24 (25%) as low and 16 (17%) as critical low using AMSTAR 2. Reviews published after the release of MECCIR had better methodological quality ratings than those published before MECCIR (odds ratio [OR] =6.61, 95% confidence interval [CI] [2.86, 15.27], p < .001). The percentages of reviews of high or moderate quality were 76% (post-MECCIR) and 39% (pre-MECCIR). Reviews co-registered with Cochrane were rated as having better methodological quality than those registered only with Campbell (OR = 5.57, 95% CI [2.13, 14.58], p < .001). The percentages of reviews of high or moderate quality were 77% versus 53% between co-registered and Campbell registered only reviews. Twenty-five of 96 reviews (26%) completely or partially reported all 27 PRISMA checklist items. The median number of items reported across reviews was 25 (IQR, 22-26). Reviews published after the release of MECCIR reported 2.80 more items than those published before MECCIR (95% CI [1.74, 3.88], p < .001); reviews co-registered on Campbell and Cochrane reported 1.98 more items than reviews only registered in Campbell (95% CI [0.72, 3.24], p = .003). An increasing trend over time was observed for both the percentage of high and moderate methodological quality of reviews and the median number of PRISMA items reported. Authors' Conclusions: Many features expected in systematic reviews were present in Campbell reviews most of the time. Methodological quality and reporting completeness were both significantly higher in reviews published after the introduction of MECCIR in 2014 compared with those published before. However, this may also reflect general improvement in the reporting the methodology of systematic reviews over time or associations with other characteristics which were not assessed such as funding or experience of teams. Reviews co-registered with Cochrane were of higher methodological quality and more complete reporting than reviews only registered in Campbell.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...